Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions

NCT07743476 | Recruiting

• 2 other identifiers: 2026-0958NCI-2026-05811
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

An observational study of patients with hematologic, oncologic, and other relevant conditions undergoing bone marrow imaging, with longitudinal collection of imaging, treatment, and clinical outcome data to characterize bone marrow features and changes over time

Conditions

Hematologic; Oncologic; Bone Marrow

Keywords

Bone Marrow Imaging; Bone Marrow Assessment; Hematologic Malignancies; Cancer Therapy; Treatment-Related Marrow Injury

Outcome Measures

Primary Outcomes (1)

• Bone marrow imaging characteristics.

  Evaluation of bone marrow imaging findings and longitudinal changes in patients with hematologic, oncologic, and other relevant conditions.

  Through study completion; an average of 1 year.

Interventions

Data Collection OTHER

Clinical, imaging, laboratory, treatment, and outcome data will be collected from institutional records and research assessments, as applicable.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

UT MD Anderson Cancer Center

You may qualify if:

• Diagnosis of a hematologic, oncologic, or other condition relevant to the study.
• Availability of clinical, imaging, laboratory, treatment, and/or outcome data relevant to the study.
• Ability to provide informed consent for prospective participation or, for pediatric participants, parent/legal guardian permission with assent when applicable.
• Participants undergoing research MRI must be eligible for MRI according to institutional safety requirements.

You may not qualify if:

• Inability to provide required informed consent or parental/legal guardian permission for prospective participation.
• Insufficient clinical information to support study participation
• Pregnancy.
• Contraindication to MRI will exclude participants from research-specific MRI but not necessarily from other study components.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

• UT MD Anderson Cancer Center

MeSH Terms

Conditions

Neoplasms; Hematologic Neoplasms

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Omran Saifi, MD

  UT MD Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Omran Saifi, MD

CONTACT

832-829-0337; OSaifi@mdanderson.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 30, 2026
• First Posted: August 4, 2026
• Study Start: August 31, 2026
• Primary Completion (Estimated): December 31, 2036
• Study Completion (Estimated): December 31, 2038
• Last Updated: September 18, 2026

Record last verified: 2026-09

Locations

US (1)